| Literature DB >> 30223600 |
Daniela Pelclova1, Vladimir Zdimal2, Martin Komarc3,4, Stepanka Vlckova5, Zdenka Fenclova6, Jakub Ondracek7, Jaroslav Schwarz8, Martin Kostejn9, Petr Kacer10, Stepanka Dvorackova11, Alexey Popov12, Pavlina Klusackova13, Sergey Zakharov14, Dhimiter Bello15.
Abstract
Thousands of researchers and workers worldwide are employed in nanocomposites manufacturing, yet little is known about their respiratory health. Aerosol exposures were characterized using real time and integrated instruments. Aerosol mass concentration ranged from 0.120 mg/m³ to 1.840 mg/m³ during nanocomposite machining processes; median particle number concentration ranged from 4.8 × 10⁴ to 5.4 × 10⁵ particles/cm³. The proportion of nanoparticles varied by process from 40 to 95%. Twenty employees, working in nanocomposite materials research were examined pre-shift and post-shift using spirometry and fractional exhaled nitric oxide (FeNO) in parallel with 21 controls. Pro-inflammatory leukotrienes (LT) type B4, C4, D4, and E4; tumor necrosis factor (TNF); interleukins; and anti-inflammatory lipoxins (LXA4 and LXB4) were analyzed in their exhaled breath condensate (EBC). Chronic bronchitis was present in 20% of researchers, but not in controls. A significant decrease in forced expiratory volume in 1 s (FEV1) and FEV1/forced vital capacity (FVC) was found in researchers post-shift (p ˂ 0.05). Post-shift EBC samples were higher for TNF (p ˂ 0.001), LTB4 (p ˂ 0.001), and LTE4 (p ˂ 0.01) compared with controls. Nanocomposites production was associated with LTB4 (p ˂ 0.001), LTE4 (p ˂ 0.05), and TNF (p ˂ 0.001), in addition to pre-shift LTD4 and LXB4 (both p ˂ 0.05). Spirometry documented minor, but significant, post-shift lung impairment. TNF and LTB4 were the most robust markers of biological effects. Proper ventilation and respiratory protection are required during nanocomposites processing.Entities:
Keywords: FeNO; exhaled breath condensate (EBC); inflammation; nanocomposites; nanoparticles; spirometry
Year: 2018 PMID: 30223600 PMCID: PMC6164906 DOI: 10.3390/nano8090731
Source DB: PubMed Journal: Nanomaterials (Basel) ISSN: 2079-4991 Impact factor: 5.076
Respiratory symptoms and disorders in the groups of subjects.
| Symptom/Disorder | Exposed | Controls | |
|---|---|---|---|
| N | 20 | 21 | |
|
| 10 (50.0%) | 9 (42.9%) | 0.758 |
|
| 7 (35.0%) | 10 (60.0%) | 0.530 |
|
| 1 (5.0%) | 1 (4.8%) | 1.000 |
|
| 5 (25.0%) | 1 (4.8%) | 0.093 |
|
| 4 (20.0%) | 0/0% | * |
|
| 3 (15.0%) | 0 (0%) | * |
Dyspnea NYHA class II = slight limitation of physical activity according to New York Heart Association (NYHA) Functional Classification. * p-values excluded from comparisons due to 0 prevalence in the controls.
Lung functions in the workers pre-shift and post-shift and in the controls.
| Examination | FVC | %FVC | VCIN (L) | %VCIN | FEV1 (L) | %FEV1 | FEV1/FVC | PEF | %PEF |
|---|---|---|---|---|---|---|---|---|---|
| Pre-shift | 4.33 ± 1.02 | 94.70 ± 13.30 | 4.36 ± 1.01 | 92.15 ± 13.04 | 3.86 ± 0.95 | 102.20 ± 13.54 | 0.89 ± 0.06 | 9.77 ± 1.95 | 110.15 ± 14.28 |
| Post-shift | 4.33 ± 0.91 | 94.95 ± 11.64 | 4.39 ± 0.90 | 93.05 ± 11.01 |
|
|
| 9.44 ± 2.06 | 106.80 ± 15.19 |
| Controls | 4.43 ± 1.05 | 100.76 ± 13.63 | 4.47 ± 1.08 | 98.71 ± 13.04 | 3.88 ± 0.96 | 106.10 ± 13.96 | 0.89 ± 0.06 | 9.72 ± 1.80 | 111.81 ± 20.17 |
FVC = forced vital capacity, FEV1 = forced expiratory volume in 1 s, VCIN = inspiratory vital capacity, PEF = peak expiratory flow, % = of predictive value for the subjects of similar characteristics (age, sex, height, and weight). comparison with the pre-shift level, p = 0.019; * comparison with the pre-shift level, p = 0.011; comparison with the pre-shift level, p = 0.031; bold numbers show significant differences
Figure 1Comparison of pre- and post-shift levels (median ± interquartile range) of inflammatory markers leukotrienes (LT) (LTB4, LTC4, LTD4, LTE4), anti-inflammatory markers lipoxins (LX) (LXA4, LXB4), and fractional exhaled nitric oxide (FeNO) in the exhaled breath condensate of 20 nanocomposite synthesis workers relative to 20 controls. * (p < 0.05) ** (p < 0.01) *** (p < 0.001).
Figure 2Comparison of pre- and post-shift levels (median ± interquartile range) of pro-inflammatory cytokines tumor necrosis factor (TNF); interleukins (IL) IL-5, IL-9; and anti-inflammatory IL-4, IL-10, and IL-13 in the exhaled breath condensate of 20 nanocomposite synthesis workers compared with 21 controls. * (p < 0.05) ** (p < 0.01) *** (p < 0.001).
Multiple regression analysis between biomarkers in exhaled breath condensate in nanocomposites production workers (regression coefficient and 95% confidence interval (CI)) and several independent variables (age, gender, alcohol, and body mass index (BMI)). Two sets of regression models were specified: (a) for controls and pre-shift data (merged, N = 41), and (b) for controls and post-shift data (merged, N = 41).
| Pre-Shift | Post-Shift | |||||||
|---|---|---|---|---|---|---|---|---|
| Markers | LTB4 | LTD4 | LTE4 | LXB4 | TNF | LTB4 | LTE4 | TNF |
|
| ||||||||
|
| −0.08 | −0.05 | 0.05 | 0.20 | −0.06 | −0.06 | ||
|
| 4.14 | −0.57 | −4.72 | −0.25 | 2.56 | 3.92 | −5.01 | 7.61 |
|
| 9.41 | 1.17 | 0.68 | −2.35 | 5.73 | 8.57 | 0.01 | 1.09 |
|
| −0.07 | 0.15 | 0.18 | 0.02 | −0.16 | −0.08 | 0.19 | −0.36 |
*** (p < 0.001), * (p < 0.05). LT—leukotrienes; LX—lipoxin; TNF—tumor necrosis factor; bold numbers show significant differences.